tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Mednax (MD), Aclaris Therapeutics (ACRS) and Eli Lilly & Co (LLY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mednax (MDResearch Report), Aclaris Therapeutics (ACRSResearch Report) and Eli Lilly & Co (LLYResearch Report).

Mednax (MD)

SVB Securities analyst Whit Mayo maintained a Hold rating on Mednax on February 3 and set a price target of $16.00. The company’s shares closed last Friday at $15.91, close to its 52-week low of $14.40.

According to TipRanks.com, Mayo is a 4-star analyst with an average return of 5.9% and a 52.6% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Privia Health Group, and Oak Street Health.

Mednax has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.

See the top stocks recommended by analysts >>

Aclaris Therapeutics (ACRS)

SVB Securities analyst Thomas Smith reiterated a Buy rating on Aclaris Therapeutics on February 2. The company’s shares closed last Friday at $14.05.

According to TipRanks.com, Smith is a 5-star analyst with an average return of 27.8% and a 51.8% success rate. Smith covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Madrigal Pharmaceuticals, and Prometheus Biosciences.

Currently, the analyst consensus on Aclaris Therapeutics is a Strong Buy with an average price target of $34.00.

Eli Lilly & Co (LLY)

In a report issued on February 2, David Risinger from SVB Securities maintained a Buy rating on Eli Lilly & Co. The company’s shares closed last Friday at $339.08.

According to TipRanks.com, Risinger is a 4-star analyst with an average return of 4.9% and a 54.2% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Theravance Biopharma, and Horizon Therapeutics.

Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $399.50, representing a 20.0% upside. In a report issued on January 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $432.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles